Sponsor · clinical trials

Taiho Oncology clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine and the EU Clinical Trials Information System (CTIS) — current trials in our USA, Spain, France, Italy, Poland, Canada, UK, Germany, South Korea, Japan, Australia, Belgium, Turkey, Brazil, Netherlands, Mexico, Singapore, Israel, Czechia, Austria, China, Portugal and EU (CTIS) registers with Taiho Oncology as lead sponsor. Synced 11 Nov 2026

14Current trials

7Recruiting now

15Drugs in these trials

23Trial registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany

Compiled from ClinicalTrials.gov and CTIS registry records · Synced 11 Nov 2026 · Editorial standards

At a glance

Taiho Oncology is the lead sponsor of 14 current clinical trials in our USA, Spain, France, Italy, Poland, Canada, UK, Germany, South Korea, Japan, Australia, Belgium, Turkey, Brazil, Netherlands, Mexico, Singapore, Israel, Czechia, Austria, China, Portugal and EU (CTIS) registers. 7 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Decitabine, Futibatinib and Zipalertinib. The most-studied condition is Acute Myeloid Leukemia.

ClinicalTrials.gov trials by status

Recruiting754%
Active, closed538%
By invitation18%

Trials by phase

Phase 2431%
Phase 1323%
Phase 3215%
Phase 2/3215%
Phase 1/2215%

Clinical trials sponsored by Taiho Oncology

13 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement NCT05727176 · Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement Drug: Futibatinib	Phase 2	Recruiting	2023-07	USA, China, Spain, Italy, Poland, Portugal, Canada, Brazil, Japan, South Korea, Australia
A Study of ARC-02 in B-cell NHL NCT07691606 · B-cell Non Hodgkin Lymphoma Drug: Rituximab	Phase 1	Recruiting	2026-06	USA, France, Spain, Italy, Poland, Australia
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment NCT04953910 · Acute Myeloid Leukemia, Myelodysplastic Syndromes Drug: Decitabine	Phase 1	Recruiting	2022-12	USA, Spain, Poland
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) NCT04256317 · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm Drugs: Azacitidine, Venclexta, Venetoclax	Phase 2/3	Recruiting	2020-05	UK, USA, Germany, France, Spain, Italy, Poland, Czechia, Canada
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection NCT07128199 · Lung Cancer, Adjuvant, Post-surgical Drug: Zipalertinib	Phase 3	Recruiting	2025-12	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Singapore, Australia
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. NCT05967689 · Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Drug: Zipalertinib	Phase 2	Recruiting	2023-07	UK, USA, Germany, France, Spain, Italy, Turkey, Canada, Japan, South Korea, Australia, Israel
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment NCT04953897 · Acute Myeloid Leukemia, Myelodysplastic Syndromes Drug: Decitabine	Phase 1	Recruiting	2021-12	USA, Spain, Poland
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) NCT04093570 · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes Drug: Decitabine	Phase 2	By invitation	2019-09	USA, Germany, France, Spain, Italy, Poland, Austria, Canada
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) NCT05973773 · Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation Drug: Zipalertinib	Phase 3	Active, closed	2023-12	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Singapore, Israel
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) NCT04657081 · Acute Myeloid Leukemia Drugs: Decitabine, Venclexta, Venetoclax	Phase 1/2	Active, closed	2021-02	USA, Spain, Canada
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas NCT02503423 · Solid Tumors, Lymphoma Drug: Tolinapant	Phase 1/2	Active, closed	2015-07	UK, USA, France, Spain, Italy, Belgium, Canada
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. NCT06506955 · Advanced/Metastatic Cancer Drug: Futibatinib	Phase 2/3	Active, closed	2024-10	UK, USA, France, Spain, South Korea
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors NCT05945823 · Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer Drugs: Adrucil, Cisplatin, Futibatinib	Phase 2	Active, closed	2023-07	USA, Germany, France, Spain

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Taiho Oncology in the EU trials register (CTIS)

1 trial

Authorised or ongoing trials in the EU Clinical Trials Information System with Taiho Oncology as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
A Study of ARC-02 in B-cell NHL 2026-525606-35-00 · CTIS ↗ · Neoplasms	Phase 1	Authorised	Spain, Poland, France + 1 more

Drugs in Taiho Oncology trials

15 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Decitabine4 Futibatinib3 Zipalertinib3 Venclexta2 Venetoclax2 Adrucil1 Azacitidine1 Cisplatin1 Irinotecan1 Keytruda1 Leucovorin1 Oxaliplatin1 Pembrolizumab1 Rituximab1 Tolinapant1

Conditions in Taiho Oncology trials

21 conditions

Acute Myeloid Leukemia5 Myelodysplastic Syndromes4Chronic Myelomonocytic Leukemia2Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation1Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations1Myelodysplastic Syndrome/Neoplasm1Lung Cancer1Adjuvant1Post-surgical1EGFR1Solid Tumors1 Lymphoma1Advanced/Metastatic Cancer1B-cell Non Hodgkin Lymphoma1Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer1Esophageal Adenocarcinoma1Esophageal Squamous Cell Cancer1Siewert Type 1 GEJ Cancer1Advanced Cholangiocarcinoma1FGFR2 Fusions1Gene Rearrangement1

By trial register

Register	Trials	Recruiting
Clinical trials in USA	13	7
Clinical trials in Spain	13	7
Clinical trials in France	9	4
Clinical trials in Italy	8	5
Clinical trials in Poland	8	6
Clinical trials in Canada	8	4
Clinical trials in UK	6	3
Clinical trials in Germany	6	3
Clinical trials in South Korea	5	3
Clinical trials in Japan	4	3
Clinical trials in Australia	4	4
Clinical trials in Belgium	3	1
Clinical trials in Turkey	3	2
Clinical trials in Brazil	3	2
Clinical trials in Netherlands	2	1
Clinical trials in Mexico	2	1
Clinical trials in Singapore	2	1
Clinical trials in Israel	2	1
Clinical trials in Czechia	1	1
Clinical trials in Austria	1	0
Clinical trials in China	1	1
Clinical trials in Portugal	1	1
EU register (CTIS)	1	—

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Acute Myeloid Leukemia

Sponsor	Trials
The First Affiliated Hospital of Soochow University	14
National Cancer Institute (NCI)	9
Assistance Publique - Hôpitaux de Paris	7
First Affiliated Hospital of Zhejiang University	6
Gruppo Italiano Malattie EMatologiche dell'Adulto	6
Zhejiang University	5
Stichting Hemato-Oncologie voor Volwassenen Nederland	4
Shenzhen Geno-Immune Medical Institute	4
Orca Biosystems	3
Shanghai Jiao Tong University School of Medicine	3

Sponsors with the most current trials registered for this condition.

Questions about Taiho Oncology trials

How many clinical trials does Taiho Oncology sponsor?

Taiho Oncology is the lead sponsor of 13 current trials on ClinicalTrials.gov in our USA, Spain, France, Italy, Poland, Canada, UK, Germany, South Korea, Japan, Australia, Belgium, Turkey, Brazil, Netherlands, Mexico, Singapore, Israel, Czechia, Austria, China and Portugal registers, and 1 authorised or ongoing trial in the EU register (CTIS), as of the registry sync on 11 November 2026. Completed and withdrawn studies are not counted.

Are Taiho Oncology trials recruiting?

Yes. 7 of its 13 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Taiho Oncology testing?

Its current trials name 15 drugs and biologicals as interventions. The most frequent are Decitabine (4), Futibatinib (3), Zipalertinib (3), Venclexta (2) and Venetoclax (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.